Logo Medical Science Monitor

Call: +1.631.470.9640
Mon - Fri 10:00 am - 02:00 pm EST

Contact Us

Logo Medical Science Monitor Logo Medical Science Monitor Logo Medical Science Monitor

01 March 2006

Trustworthy alteration and improvement in adjuvant treatment of colon cancer.

Ali Harlak, Atilla Soran

Med Sci Monit 2006; 12(3): RA46-52 :: ID: 447119

Abstract

Colorectal cancer is the third most common cancer both in men and womenin the United States. Advances in adjuvant treatment of colon cancer have came to consist of a successionof small improvements by large-scale clinical trials. The National Surgical Adjuvant Breast and BowelProject (NSABP) colon trials reflect the exciting history of progress in adjuvant treatment of coloncancer. Since 1977, the NSABP has successfully designed and conducted seven large-scale prospective randomizedclinical trials for colon cancers that has altered and improved the standard of care for patients withthis disease. More than 5,000 physicians, nurses, and other medical professionals at nearly 200 medicalsites from across the United States, Canada, Puerto Rico, Australia and New Zealand assist the NSABPin its mission to eliminate colorectal and breast cancers. These medical sites include several universityhospitals and many other local medical centers that treat patients from a variety of social, and economicbackgrounds contributed to the trials. The NSABP clinical trials are distinctive because of the largenumber of patients and elimination of social, cultural and economic influences. The ongoing trials ofthe NSABP should continue to provide information used to determine principals of neoadjuvant treatmentfor colon cancer. In this article we review seven prospective randomized clinical trials with their publishedresults and discuss the combined analysis of the first four trials.

Keywords: Clinical Trials as Topic, Chemotherapy, Adjuvant - statistics & numerical data, Colonic Neoplasms - therapy, Combined Modality Therapy, Disease-Free Survival, Follow-Up Studies, Time Factors

Add Comment 0 Comments

Editorial

01 May 2024 : Editorial  

Editorial: First Regulatory Approval for Adoptive Cell Therapy with Autologous Tumor-Infiltrating Lymphocytes (TILs) – Lifileucel (Amtagvi)

Dinah V. Parums

DOI: 10.12659/MSM.944927

Med Sci Monit 2024; 30:e944927

In Press

Clinical Research  

Differential Inflammatory Responses in Adult and Pediatric COVID-19 Patients: Implications for Long-Term Co...

Med Sci Monit In Press; DOI: 10.12659/MSM.944052  

Clinical Research  

Effectiveness of Shoulder Taping in Treating Hemiplegic Shoulder Subluxation: A Randomized Controlled Study...

Med Sci Monit In Press; DOI: 10.12659/MSM.944222  

Clinical Research  

Comparison of Fentanyl, Ketamine, and Lidocaine Combined with Propofol Anesthesia in Patients with Crohn Di...

Med Sci Monit In Press; DOI: 10.12659/MSM.944116  

Database Analysis  

ANXA5: A Key Regulator of Immune Cell Infiltration in Hepatocellular Carcinoma

Med Sci Monit In Press; DOI: 10.12659/MSM.943523  

Most Viewed Current Articles

17 Jan 2024 : Review article  

Vaccination Guidelines for Pregnant Women: Addressing COVID-19 and the Omicron Variant

DOI :10.12659/MSM.942799

Med Sci Monit 2024; 30:e942799

0:00

14 Dec 2022 : Clinical Research  

Prevalence and Variability of Allergen-Specific Immunoglobulin E in Patients with Elevated Tryptase Levels

DOI :10.12659/MSM.937990

Med Sci Monit 2022; 28:e937990

0:00

16 May 2023 : Clinical Research  

Electrophysiological Testing for an Auditory Processing Disorder and Reading Performance in 54 School Stude...

DOI :10.12659/MSM.940387

Med Sci Monit 2023; 29:e940387

0:00

01 Jan 2022 : Editorial  

Editorial: Current Status of Oral Antiviral Drug Treatments for SARS-CoV-2 Infection in Non-Hospitalized Pa...

DOI :10.12659/MSM.935952

Med Sci Monit 2022; 28:e935952

0:00

Your Privacy

We use cookies to ensure the functionality of our website, to personalize content and advertising, to provide social media features, and to analyze our traffic. If you allow us to do so, we also inform our social media, advertising and analysis partners about your use of our website, You can decise for yourself which categories you you want to deny or allow. Please note that based on your settings not all functionalities of the site are available. View our privacy policy.

Medical Science Monitor eISSN: 1643-3750
Medical Science Monitor eISSN: 1643-3750